

Press Release  
02 February 2022 11:00:00 CET



## Newbury Pharmaceuticals has been approved for listing on Nasdaq First North Growth Market

Newbury Pharmaceuticals AB has received approval for admission to trading on the Nasdaq First North Growth Market. The first day of trading on Nasdaq First North Growth Market is scheduled for February 4, 2022, under the short name NEWBURY.

### For more information, contact:

---

Lars Minor, CEO  
[lars.minor@newburypharma.com](mailto:lars.minor@newburypharma.com)  
Mobile: +46 72-377 3005

[www.newburypharma.com](http://www.newburypharma.com)

### About Newbury Pharmaceuticals

---

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at [ca@vhcorp.se](mailto:ca@vhcorp.se) or +46 (0) 40 200 250.

### Attachments

---

[Newbury Pharmaceuticals has been approved for listing on Nasdaq First North Growth Market](#)